Vaccines: A review of immune-based interventions to prevent and treat disease

Journal of Clinical Pharmacology

Volumn 55, Issue S3, 2015, Pages S93-S102

  Alemayehu, Demissie ^a   Utt, Eric ^a   Knirsch, Charles ^a  

^a PFIZER INC   (United States)

Author keywords

life cycle management; regulatory pathways; therapeutic protein; vaccine development; viral vectors

Indexed keywords

VACCINE;

ANTIBIOTIC RESISTANCE; ARTICLE; CLINICAL RESEARCH; DRUG INDUSTRY; HUMAN; INFECTION PREVENTION; NONHUMAN; PLANNING; PRODUCTIVITY; VACCINE PRODUCTION; ANIMAL; COMMUNICABLE DISEASES; DRUG LEGISLATION; INFECTION CONTROL; MEDICAL RESEARCH;

ANIMALS; BIOMEDICAL RESEARCH; COMMUNICABLE DISEASE CONTROL; COMMUNICABLE DISEASES; HUMANS; LEGISLATION, DRUG; VACCINES;

EID: 84923363787     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.397     Document Type: Article

References (72)

1. Centers for Disease Control and Prevention (CDC),. Ten Great Public Health Achievements-United States, 1900-1999. Morbidity and Mortality Weekly Report (MMWR). 1999; 48 (12): 241-243.
2. Levine MM, Dougan G, Kaper JB, et al. eds. New Generation Vaccines. 3rd ed. Informa Healthcare; CRC Press; Boca Raton; FL 2004.
3. Snape MD, Pollard AJ,. Meningococcal polysaccharide-protein conjugate vaccines. Lancet Infect Dis. 2005; 5: 21-30.
4. Siegrist CA,. The challenges of vaccine responses in early life: selected examples. J Comp Pathol. 2007; 137 (Suppl 1): S4-S9.
5. Artz AS, Ershler WB, Longo DL,. Pneumococcal vaccination and revaccination of older adults. Clin Microbiol Rev. 2003; 16: 308-318.
6. Alemayehu D, Quinn J, Cook J, Kunkel M, Knirsch CA,. A paradigm shift in drug development for treatment of rare multidrug resistant Gram-negative pathogens. Clin Infect Dis. 2012; 55 (4): 562-567.
7. Rex JH, Eisenstein BI, Alder J, et al. A comprehensive regulatory framework to address the unmet need for new antibacterial treatments. Lancet Infect Dis. 2013; 13 (3): 269-275.
8. Smith JS,. Patenting the Sun: Polio and the Salk Vaccine. William Morrow & Co; New York, NY 1990.
9. Interlandi J. New Anti-Addiction Vaccines. Newsweek (April 14, 2011). http://www.newsweek.com/new-anti-addiction-vaccines-87261.
10. Curtiss R III,. The impact of vaccines and vaccinations: challenges and opportunities for modelers. Math Biosci Eng. 2011; 8:(1): 77-93.
11. Akira A, Uematsu S, Takeuchi O,. Pathogen recognition and innate immunity. Cell. 2006; 124 (4): 783-801.
12. Klebanoff CA, Gattinoni L, Restifo NP,. CD8+ T-cell memory in tumor immunology and immunotherapy. Immunol Rev. 2006; 211: 214-224.
13. Curtsinger JM, Lins DC, Mescher MF,. Signal 3 determines tolerance versus full activation of naive CD8 T cells: dissociating proliferation and development of effector function. J Exp Med. 2003; 197: 1141-1151.
14. Delany I, Rappuoli R, Seib KL,. Vaccines, reverse vaccinology, and bacterial pathogenesis. Cold Spring Harb Perspect Med. 2013; 3: a012476.
15. Draper SJ, Heeney JL,. Viruses as vaccine vectors for infectious diseases and cancer. Nat Rev Microbiol. 2010; 8: 62-73.
16. De Groot AS, Sbai H, Aubin CS, et al. Immuno informatics: mining genomes for vaccine components. Immunol Cell Biol. 2002; 80 (3): 255-269.
17. Pronker ES, Weenen TC, Commandeur H, et al. Risk in vaccine research and development quantified. PLoS ONE. 5775; 8 (3): e57755.
18. Blackstock WP, Weir MP,. Proteomics: quantitative and physical mapping of cellular proteins. Trends Biotechnol. 1999; 17: 121-127.
19. Choi Y, Chang J. Viral vectors for vaccine applications. Clin Exp Vaccine Res. 2013;2:97-105. http://dx.doi.org/10.7774/cevr.2013.2.2.97.
20. Moingeon P, de Taisne C, Almond J,. Delivery technologies for human vaccines. Br Med Bull. 2002; 62: 29-44.
21. Danthinne X, Imperiale MJ,. Production of first generation adenovirus vectors: a review. Gene Ther. 2000; 7 (20): 1707-1714.
22. Banchereau J, Steinman RM,. Dendritic cells and the control of immunity. Nature. 1998; 392: 245-252.
23. Yamada K, Morishita N, Katsuda T, Kubo S, Gotoh A, Yamaji H,. Adenovirus vector production using low-multiplicity infection of 293 cells. Cytotechnology. 2009; 59 (3): 153-160.
24. Gabitzsch ES, et al. Novel adenovirus type 5 vaccine platform induces cellular immunity against HIV-1 gag, Pol, Nef despite the presence of Ad5 immunity. Vaccine. 2009; 27: 6394-6398.
25. Sekaly RP,. The failed HIV Merck vaccine study: a step back or a launching point for furture vaccine development?. J Cell Biol. 2008; 205 (1): 7-12.
26. "Statement: NIH Discontinues Immunizations in HIV Vaccine Study". niaid.nih.gov. 25 April 2013.
27. Schultz BR, Chamberlain JC,. Recombinant adeno-associated virus transduction and integration. Mol Ther. 2008; 16 (7): 1189-1199.
28. Rollier CS, et al. Viral vectors as vaccine platforms: deployment in sight. Curr Opin Immunol. 2011; 23 (3): 377-382.
29. Hu B, Tai A, Wang P,. Immunization delivered by lentiviral vectors for cancer and infectious diseases. Immunol Rev. 2011; 239 (1): 45-61.
30. Lundstrom K,. Biology and application of alphaviruses in gene therapy. Gene Ther. 2005; 12 (suppl 1): s92-s97.
31. Schlesinger S,. Alphavirus vectors: development and potential therapeutic applications. Expert Opin Biol Ther. 2001; 1 (2): 177-191.
32. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research. Guidance for Industry: Considerations for Developmental Toxicity Studies for Preventive and Therapeutic Vaccines for Infectious Disease Indications. http://www.fda.gov/biologicsbloodvaccines/guidancecomplianceregulatoryinformation/guidances/vaccines/ucm074827.htm.
33. Cook IF,. Evidence based route of administration of vaccines. Hum Vaccin. 2008; 4 (1): 67-73. Epub 2007 Jul 15.
34. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research. Guidance for Industry: How to Complete the Vaccine Adverse Event Reporting System Form (VAERS-1). https://www.google.com/url?q=http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/UCM164319.pdf&sa=Uei=7JgkU92JGNSa0gGnzYHwDg&ved=0CBsQFjAAusg=AFQjCNELFhbW25Z-srviwjusL0MSKvchBg.
35. Ellenberg S,. Safety considerations for new vaccine development. Pharmacoepidemiol Drug Safety. 2001; 10: 1-5.
36. International Conference on Harmonisation; FDA Guidance for Industry: E11 Clinical Investigation of Medicinal Products in the Pediatric Population, December 2000. http://www.fda.gov/cber/gdlns/ichclinped.pdf.
37. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research. Guidance for Industry: Considerations for Developmental Toxicity Studies for Preventive and Therapeutic Vaccines for Infectious Disease Indications. http://www.fda.gov/biologicsbloodvaccines/guidancecomplianceregulatoryinformation/guidances/vaccines/ucm074827.htm.
38. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research. 199. Guidance for Industry: Content and Format of Chemistry, Manufacturing and Controls Information and Establishment Description Information for a Vaccine or Related Product. https://www.google.com/url?q=http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Allergenics/ucm072451.htm&sa=U&ei=GpkkU-3vG8mT0gHguoH4Dw&ved=0CCQQFjAB&usg=AFQjCNF3Q7KdttyqM7LG-AsL-Imj2qJw.
39. Cutts FT, Enwere G, Zaman SMA, Yallop FG,. Operational challenges in large clinical trials: examples and lessons learned from the Gambia pneumococcal vaccine trial. PLoS Clin Trial. 2006; 1 (3): e16. doi: 10.1371/journal.pctr.0010016.
40. Food and Drug Administration. Fast Track, Breakthrough Therapy, Accelerated Approval and Priority Review. Expediting Availability of New Drugs for Patients with Serious Conditions. http://www.fda.gov/forconsumers/byaudience/forpatientadvocates/speedingaccesstoimportantnewtherapies/ucm128291.htm.
41. Snoy PJ,. Establishing efficacy of human products using animals: the US food and drug administration's "animal rule". Vet Pathol. 2010; 47 (5): 774-778. doi: 10.1177/0300985810372506. Epub 2010 Jun 15.
42. U. S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research. Guidance for Industry: Clinical Data Needed to Support the Licensure of Pandemic Influenza Vaccines.
43. Zwarenstein M, Treweek S, Gagnier JJ, et al. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ. 2008; 337: a2390.
44. Schuchat A, et al. Active bacterial core surveillance of the emerging infections program network. Emerg Infect Dis [serial on the Internet]. 2001 Jan-Feb [date cited]. http://wwwnc.cdc.gov/eid/article/7/1/70-0092.htm.
45. U. S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research. Guidance for IndustryGeneral Principles for the Development of Vaccines to Protect Against Global Infectious Diseases.
46. http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm074786.htm.
47. Chaudhri R, Borriello G, Anderson R,. Pervasive computing technologies to monitor vaccine cold chains in developing countries. IEEE Pervasive Computing. Special Issue on Information and Communication Technologies for Development. 2012.
48. Center for Disease Control and Prevention. Vaccine. http://www.cdc.gov/vaccines/schedules/hcp/child-adolescent.html.
49. Center for Disease Control and PreventionVaccine. http://www.cdc.gov/vaccines/schedules/hcp/adult.html.
50. 2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host. Clin Infect Dis. (2014);58(3):e44-e100. DOI: 10.1093/cid/cit684. http://m.cid.oxfordjournals.org/content/early/2013/11/26/cid.cit684.full.
51. Hibberd PL. Immunization in patients with cance. http://www.uptodate.com/contents/immunizations-in-patients-with-cancer.
52. U. S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research. Guidance for Industry: Clinical Considerations for Therapeutic Cancer Vaccines. https://www.google.com/url?q=http://www.fda.gov/downloads/biologicsbloodvaccines/guidancecomplianceregulatoryinformation/guidances/vaccines/ucm278673.pdf&sa=U&ei=rZYkU5XpHrGU0gG0tYGYBw&ved=0CBsQFjAA&usg=AFQjCNGkK4g5HWBHmIxey4ub9CIk0drXjA.
53. Klebanoff CA, Acquavella N, Yu Z, Restifo NP,. Therapeutic cancer vaccines: are we there yet? Immunol Rev. 2011; 239 (1): 27-44.
54. Kantoff PW, Higano CS, Shore ND,. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010; 363 (5): 411-422.
55. Giarelli E,. " Cancer vaccines: a new frontier in prevention and treatment ". Oncology (Williston Park). 2007; 21 (11 Suppl Nurse Ed): 11-7; Discussion 18.
56. Moingeon P, Almond J, de Wilde M,. Therapeutic vaccines against infectious diseases. Curr Opin Microbiol. 2003; 6 (5): 462-471.
57. Fauci AS, Marston DM,. Ending AIDS-Is an HIV vaccine necessary? N Engl J Med. 2014; 370: 495-498.
58. Hicks MJ, Kaminsky SM, De BP, et al. Fate of systemically administered cocaine in nonhuman primates treated with the dAd5GNE anticocaine vaccine. Hum Gene Ther Clin Dev. 2014; 25 (1): 40-49.
59. Gregorio ED, Caproni E, Ulmer JB,. Vaccine adjuvants: mode of action. Front. Immunol. 2013; 4:214: 1-6. doi: 10.3389/fimmu.2013.00214.
60. Sayers S, Ulysse G, Xiang Z, He Y,. " Vaxjo: a web-based vaccine adjuvant database and its application for analysis of vaccine adjuvants and their uses in vaccine development ". J Biomed Biotechnol. 2012; 2012: 831486.
61. Shah HB, Devera TS, Rampuria P, Lang GA, Lang ML,. Type II NKT cells facilitate alum-sensing and humoral immunity. J Leukoc Biol. 2012; 92: 883-893.
62. Lambrecht BN, et al. Mechanism of action of clinically approved adjuvants. Curr Opin Immunol. 2009; 21 (1): 23-29.
63. Rajput ZI, et al. Adjuvant effects of saponins on animal immune responses. J Zhejiang Univ Sci B. 2007; 8 (3): 153-161.
64. Bode C, Zhao G, Steinhagen F, Klinman DM,. CpG DNA as a vaccine adjuvant. Expert Rev Vaccines. 2011; 10 (4): 499-511.
65. Reed SG, Orr MT, Fox CB,. Key roles of adjuvants in modern vaccines. Nat Med. 2013; 19 (12): 1597-1608.
66. Rathore P, Swami G,. Virosomes: a novel vaccination technology. IJPSR. 2012; 3 (10): 3591-3597.
67. De Gregorio E, Caproni E, Ulmer JB,. Vaccine adjuvants: mode of action. Front Immunol. 2013; 4: 214. doi: 10.3389/fimmu.2013.00214.
68. Wang WW, Mehrotra DV, Chan IS, Heyse JF,. Statistical considerations for noninferiority/equivalence trials in vaccine development. J Biopharm Stat. 2006; 16 (4): 429-441.
69. Chan ISF, Bohidar NR,. Exact power and sample size for vaccine efficacy studies. Commun Stat-Theory Methods. 1998; 27: 1305-1322.
70. O'Neill RT,. On sample sizes to estimate the protective efficacy of a vaccine. Stat Med. 1988; 7: 1279-1288.
71. Prentice RL,. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med. 1989; 8: 431-440.
72. Buyse M, Molenberghs G,. The validation of surrogate endpoints in randomized experiments. Biometrics. 1998; 54: 1014-1029.